surmount-osa tirzepatide results In a prespecified secondary analysis of the trial it was found that improves cardiometabolic outcomes in patients with moderate-to-severe OSA and obesity Tirzepatide (Zepbound®): Its Effects on

Never exceed conservative dosing: Doses above 5060 mcg/day lack robust clinical research support and may substantially increase adverse effect risk [2]

With brand names like Ozempic and Wegovy making headlines daily, many people are left wondering: what is semaglutide, and is it really the breakthrough everyone claims it to be

Drug Healthc Patient Saf 14:113124

We monitor your progress and check in regularly so adjustments happen safely, not by guesswork

Major Weight Loss Results In a Phase 2 clinical trial with 338 adults, participants on the highest dose lost an average of 24.2% of their body weight in 48 weeks

Typically, you must stop GLP-1 agonists 1 to 2 weeks before elective surgery to reduce the risk of aspiration under anesthesia